Promising combo for prostate cancer halted early
NCT ID NCT02555189
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at adding ribociclib to the standard hormone therapy enzalutamide for men with a certain type of advanced prostate cancer that had spread and no longer responded to hormone therapy alone. The goal was to find the best dose and see if the combination could lower PSA levels. The study was stopped early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
-
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a three-drug cocktail outsmart resistant prostate cancer?
- New hope for advanced bladder cancer? bevacizumab combo tested
- Supercharged immune cells take on Hard-to-Treat prostate cancer
- New PET scan agent aims to map hidden prostate cancer spread
- New drug combo aims to halt tough prostate cancer